Detail akcie Penumbra online

Business Summary: Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Penumbra Inc revenues increased 16% to $324.1M. Net income increased from $11M to $39.2M. Revenues reflect Vascular segment increase of 21% to $226.5M, Neuro segment increase of 7% to $97.6M, United States segment increase of 23% to $256.9M. Net income benefited from Research and Development - Other decrease of 11% to $19.9M (expense), Amort Intangibles excl Goodwill in SGA decrease of 96% to $104K (expense).